Payload Information
General Information of This Payload
| Payload ID | PAY0GEDDB |
|||||
|---|---|---|---|---|---|---|
| Name | PF-06464368 |
|||||
| Target(s) | Unclear | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
PF-06688992 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03159117 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1 open-label dose escalation of GD3 ADC (PFIZER PF-06688992) in subjects with unresectable stage 3 or stage 4 malignant melanoma (b802wi209568).
|
||||
References